Revised forecast
Fiscal year ending May 2026 · Full yearPrevious forecast published 11 July 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue is expected to be lower than forecast due to inventory adjustments by customers and changes to the sales strategy in the Chinese market. Profit is expected to be higher than forecast due to an increase in the formulation ratio, lower research and development expenses resulting from revisions to the development plan and the timing shift of bioequivalence studies, lower depreciation expenses following changes to accounting standards, and lower expenses resulting from Smart Spending.
| Item | Details |
|---|---|
| Net Sales | 52,500 million yen → 51,000 million yen（-2.9%） |
| Operating profit | 3,000 million yen → 3,300 million yen（+10.0%） |
| Ordinary income | 3,000 million yen → 3,500 million yen（+16.7%） |
| Profit attributable to owners of the parent | 2,300 million yen → 2,500 million yen（+8.7%） |
| Net income per share | 76.70 yen and sen → 84.38 yen and sen |
| Fiscal Period Covered | Fiscal year ending May 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 11 July 2025 |
| Previous-period results | Consolidated results for the fiscal year ended May 2025: revenue ¥50,643 million, operating profit ¥2,619 million, ordinary profit ¥2,705 million, net income attributable to owners of the parent ¥1,908 million, and consolidated earnings per share of ¥62.74 |
| Reason for the revision | Revenue is expected to be lower than forecast due to inventory adjustments by customers and changes to the sales strategy in the Chinese market. Profit is expected to be higher than forecast due to an increase in the formulation ratio, lower research and development expenses resulting from revisions to the development plan and the timing shift of bioequivalence studies, lower depreciation expenses following changes to accounting standards, and lower expenses resulting from Smart Spending. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue is expected to be lower than forecast due to inventory adjustments by customers and changes to the sales strategy in the Chinese market. Meanwhile, profit is expected to be higher than forecast due to an increase in the formulation ratio, lower research and development expenses resulting from revisions to the development plan and the timing shift of bioequivalence studies, lower depreciation expenses following changes to accounting standards, and lower expenses overall.